Novartis Investigative Site

Summary

Novartis Investigative Site is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Breast Cancer, Pancreatic Cancer, Multiple Sclerosis, Cancer, Relapse and other specialties. Novartis Investigative Site is involved with conducting 289 clinical trials across 346 conditions. There are 0 research doctors associated with this hospital, such as .

Top PIs

Clinical Trials running at Novartis Investigative Site

Breast Cancer

Multiple Sclerosis

Prostate Cancer

Brain Tumor

Breast cancer

Pancreatic Cancer

Colorectal Cancer

Follicular Lymphoma

Relapse

Lung Cancer

Ribociclib + Hormone Therapy

for Breast Cancer

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).

Recruiting

2 awards

Phase 3

4 criteria

[177Lu]Lu-DFC413

for Breast Cancer

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-DFC413 and safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with solid tumors

Recruiting

1 award

Phase 1

1 criteria

[177Lu]Lu-NeoB + Capecitabine

for Metastatic Breast Cancer

In the phase I part, to determine the recommended doses (RD) and dosing regimens of \[177Lu\]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor. In the phase II part, to evaluate the preliminary anti-tumor activity of two different doses/regimens of \[177Lu\]Lu-NeoB in combination with capecitabine (dose optimization).

Recruiting

1 award

Phase 1 & 2

5 criteria